Galderma backs new evidence for Sculptra and Restylane in fast-evolving patient demand segments
Read how Galderma’s new interim data could influence aesthetic treatment planning in menopause and GLP-1-related volume loss.
Why Innovent Biologics’ tri-specific IBI3055 matters in the race to deplete both B cells and plasma cells
Innovent Biologics unveiled preclinical IBI3055 data in autoimmune disease. Read what this could change for immune-reset therapies.
ArkBio pushes AK0406 into first-in-human testing, but can a long-acting flu antiviral carve out real clinical space?
ArkBio has begun Phase I testing of AK0406 in Australia. Read why this long-acting influenza candidate matters and what risks still need proving.
Can Junction’s GRAIL tie-up do what clinical data alone could not for Galleri adoption?
Junction and GRAIL are expanding Galleri access, but can workflow integration overcome regulatory, reimbursement, and adoption hurdles? Read more.
Can Arrowhead Pharmaceuticals expand plozasiran without the Ionis patent fight becoming a commercial overhang?
Arrowhead Pharmaceuticals is advancing plozasiran fast, but can it overcome the Ionis patent dispute? Read the deeper legal and commercial analysis.
Why Tubulis gives Gilead more than just another antibody-drug conjugate asset
Gilead is acquiring Tubulis to expand its antibody-drug conjugate pipeline. Read what the deal changes for oncology strategy and ADC competition.
Why Galderma is turning ALASTIN into a clinic workflow strategy, not just a skincare brand
Galderma’s ALASTIN Signature Practices aim to embed skincare into aesthetic workflows. Read what this means for clinics, competition, and growth.
Why the Terns acquisition matters more for Merck’s long-term pipeline strategy than its near-term revenue
Merck has begun its tender offer for Terns Pharmaceuticals. Read what the deal could change for metabolic drug competition and pipeline strategy.
Can Alcon turn baseball fandom into a growth engine for Systane in Canada’s dry eye category?
See how Alcon is using the Toronto Blue Jays to expand Systane’s dry eye reach in Canada and what it means for eye care competition.
Acadia Pharmaceuticals broadens Rett syndrome treatment flexibility with DAYBUE STIX rollout in the United States
Acadia Pharmaceuticals has launched DAYBUE STIX for Rett syndrome in the U.S. Read what this means for adoption, tolerability, and market strategy.